Omega Fund Management, LLC Long-Term Concentrated

Location: Boston, MA

CIK: 0001637359 · Show all filings

Period: Q1 2026 (← Previous) (Next →)

Filing Date: May 15, 2026

Total Value: $163M (100.0% shares, 0.0% debt)

Holdings (10)

BCAX Bicara Therapeutics Inc. 29.2%

Value $47.58M Shares 2,392,150 Est. Cost $24.78 Unrealized -34.3%

NUVB Nuvation Bio Inc. 21.2%

Value $34.67M Shares 8,081,089 Est. Cost $11.18 Unrealized -44.7%

BBOT BridgeBio Oncology Therapeutics Inc. 18.0%

Value $29.44M Shares 3,289,661 Est. Cost $11.58 Unrealized —

KMTS Kestra Med Technologies Ltd 12.5%

Value $20.37M Shares 1,022,149 Est. Cost $22.98 Unrealized +9.6%

BBNX Beta Bionics Inc. 8.1%

Value $13.19M Shares 1,316,183 Est. Cost $18.64 Unrealized -8.3%

ENGN enGene Holdings Inc. 3.7%

Value $5.968M Shares 876,357 Est. Cost $9.45 Unrealized +2.3%

ALMS Alumis Inc. 3.3%

Value $5.315M Shares 241,255 Est. Cost $13.30 Unrealized +82.9%

SANA Sana Biotechnology, Inc. 1.5%

Value $2.43M Shares 843,750 Est. Cost $32.56 Unrealized -86.7%

IMA ImageneBio, Inc. 1.4%

Value $2.277M Shares 455,361 Est. Cost $13.25 Unrealized -47.9%

REPL Replimune Group 1.2%

Value $1.91M Shares 248,672 Est. Cost $17.40 Unrealized -55.1%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
BCAX	Bicara Therapeutics Inc.	2,392,150	$47.58M	29.2%	$24.78	-34.3%	Common Stock	055477103
NUVB	Nuvation Bio Inc.	8,081,089	$34.67M	21.2%	$11.18	-44.7%	Common Stock Class A	67080N101
BBOT	BridgeBio Oncology Therapeutics Inc.	3,289,661	$29.44M	18.0%	$11.58	—	Common Stock	107924102
KMTS	Kestra Med Technologies Ltd	1,022,149	$20.37M	12.5%	$22.98	+9.6%	Common Stock	G52441105
BBNX	Beta Bionics Inc.	1,316,183	$13.19M	8.1%	$18.64	-8.3%	Common Stock	08659B102
ENGN	enGene Holdings Inc.	876,357	$5.968M	3.7%	$9.45	+2.3%	Common Stock	29286M105
ALMS	Alumis Inc.	241,255	$5.315M	3.3%	$13.30	+82.9%	Common Stock	022307102
SANA	Sana Biotechnology, Inc.	843,750	$2.43M	1.5%	$32.56	-86.7%	Common Stock	799566104
IMA	ImageneBio, Inc.	455,361	$2.277M	1.4%	$13.25	-47.9%	Common Stock	45175G207
REPL	Replimune Group	248,672	$1.91M	1.2%	$17.40	-55.1%	Common Stock	76029N106